Trump's prescription: Indian drug units may face stricter check-ups

Following President Trump's executive order, the Indian pharmaceutical industry anticipates a surge in unannounced inspections by the US FDA, causing concerns about compliance and potential trade barriers. Experts suggest that companies should diversify their business and invest in innovation to mitigate risks associated with increased scrutiny and potential disruptions in API sourcing from China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EGohnge
via IFTTT